Genmab A/S (GMAB)
27.70
-1.05
(-3.65%)
USD |
NASDAQ |
May 02, 16:00
29.11
+1.41
(+5.09%)
After-Hours: 05:07
Genmab Free Cash Flow (Quarterly): 228.45M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 228.45M |
| September 30, 2023 | 282.74M |
| June 30, 2023 | 54.16M |
| March 31, 2023 | 451.53M |
| December 31, 2022 | 61.92M |
| September 30, 2022 | 244.28M |
| June 30, 2022 | 123.48M |
| March 31, 2022 | 79.95M |
| December 31, 2021 | 28.57M |
| September 30, 2021 | 53.61M |
| June 30, 2021 | 44.68M |
| March 31, 2021 | 187.56M |
| December 31, 2020 | -158.20M |
| September 30, 2020 | 808.85M |
| June 30, 2020 | 13.97M |
| March 31, 2020 | 274.00M |
| December 31, 2019 | 22.93M |
| September 30, 2019 | 39.49M |
| June 30, 2019 | 24.33M |
| March 31, 2019 | 95.42M |
| December 31, 2018 | 29.84M |
| September 30, 2018 | -33.09M |
| June 30, 2018 | 16.50M |
| March 31, 2018 | 71.81M |
| December 31, 2017 | 27.43M |
| Date | Value |
|---|---|
| September 30, 2017 | 15.16M |
| June 30, 2017 | 78.56M |
| March 31, 2017 | 107.17M |
| December 31, 2016 | -15.80M |
| September 30, 2016 | 30.10M |
| June 30, 2016 | 31.37M |
| March 31, 2016 | -1.884M |
| December 31, 2015 | 35.15M |
| September 30, 2015 | 20.04M |
| June 30, 2015 | -17.62M |
| March 31, 2015 | -11.38M |
| December 31, 2014 | 1.176M |
| September 30, 2014 | 4.282M |
| June 30, 2014 | 8.822M |
| March 31, 2014 | -4.072M |
| December 31, 2013 | -3.266M |
| September 30, 2013 | -9.530M |
| June 30, 2013 | -4.568M |
| March 31, 2013 | -7.272M |
| December 31, 2012 | -6.224M |
| September 30, 2012 | 42.61M |
| June 30, 2012 | -13.44M |
| March 31, 2012 | -12.25M |
| December 31, 2011 | -21.15M |
| September 30, 2011 | -19.57M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-158.20M
Minimum
Dec 2020
808.85M
Maximum
Sep 2020
150.86M
Average
61.92M
Median
Dec 2022
Free Cash Flow (Quarterly) Benchmarks
| Ascendis Pharma A/S | -43.27M |
| Novo Nordisk A/S | 772.71M |
| Galecto Inc | -11.47M |
| Evaxion Biotech AS | -- |
| IO Biotech Inc | -22.91M |